To compare the effects two high-protein (HP) diets that differ in dietary calcium and protein source on weight loss, body composition, glucose and lipid metabolism, markers of liver function, fibrinolysis and endothelial function and blood pressure. DESIGN: Randomized, parallel study (12 wk of energy restriction, 4 wk of energy balance) of high dairy protein/high-calcium (DP, 2400 mg Ca/d) and high mixed protein/moderate calcium (MP, 500 mg Ca/d) diets (5.5 MJ/d, 34% protein, 41% carbohydrate, 24% fat). SUBJECTS: In all, 50 healthy, overweight (age 25-64 y; body mass index 25-35 kg/m 2 ;) males (n ¼ 20) and females (n ¼ 30). RESULTS: Loss of total weight (À9.773.8 kg), fat mass (À8.370.4 kg) and lean mass (À1.670.3 kg) were independent of dietary group. Improvements in fasting insulin, lipids, systolic/diastolic blood pressure, and markers of liver function, fibrinolysis and endothelial function were independent of dietary intervention. CONCLUSIONS: Increased dietary calcium/dairy foods in an energy-restricted, HP diet does not affect weight loss or body composition. Weight reduction following increased protein diets is associated with beneficial metabolic outcomes that are not affected by protein source.
Introduction
The prevalence of overweight and obese adults has dramatically increased and this parallels increased energy consumption. 1 Observational studies have shown an inverse relationship between dietary calcium intake (particularly from dairy sources) and body fat/weight, [2] [3] [4] [5] [6] although not consistently observed. 7 Similarly, dietary patterns with a high intake of dairy food/calcium have been linked to reduced incidence of insulin resistance in overweight adults, 8 lower blood pressure 9 and improved lipid profile. 5 This relationship between calcium intake and body weight is observed in transgenic mice susceptible to diet-induced obesity. Fat pad mass is lower after consumption of diets high in calcium carbonate or dairy calcium compared to an equicaloric, low-calcium, high-fat, high-sucrose diet. 10 Highcalcium diets result in greater loss of total and fat pad mass, increased lipolysis and lower lipogenesis compared to the control diet when the energy intake of obese mice is reduced to 70% of ad libitum consumption.
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Unintentional weight loss (À4.9 kg of fat mass) occurred after 1 y of increased calcium intake (1000 mg/d) in obese African-Americans. 10 Overweight adults following an energy-restricted (À2000 kJ/d) diet that was high in dairy foods/calcium (1200-1300 mg Ca/d) had greater loss of total body weight and fat mass compared to a calcium-supplemented group (1200-1300 mg/d), and the latter group's weight loss was greater than a low-calcium, placebo-treated group (400-500 mg Ca/d). 12 However, this relationship is not consistently observed; weight loss was similar following energy-restricted diets that differed in dietary calcium.
An ad libitum diet with a moderate increase in the protein to carbohydrate ratio also showed enhanced weight loss compared to a higher carbohydrate diet. 15 Smaller lean mass losses are observed following energy-controlled, high-protein (HP) weight loss diets. 14, 16 It is unclear whether these outcomes are affected by the source of protein. The impact of HP diets on other safety markers requires demonstration. Therefore, the aim of this study was to compare the effect of two isocaloric, energy-restricted HP diets that differ in dietary calcium and protein source on weight loss and body composition in healthy, overweight adults. Also, we aimed to assess changes in metabolic parameters and risk markers for comorbidities of obesity following weight loss on HP diets that differ in protein source.
Method
Subjects Subjects were recruited by public advertisement and 69 subjects satisfied all inclusion (body mass index (BMI) 27-40 kg/m 2 ; age 20-65 y) and exclusion criteria (lactose intolerance, widely fluctuating exercise patterns, use of calcium supplements, medications or medical conditions known to affect lipid and glucose metabolism and lactating or pregnant, if female). The study was approved by the Commonwealth Scientific Industrial Research Organisation (CSIRO), Division of Health Sciences and Nutrition Human Ethics Committee. All subjects gave informed, written consent to participate. Nine subjects withdrew from the study prior to commencement. In all, 10 subjects withdrew after commencement (DP n ¼ 5, MP n ¼ 5) due to illness (n ¼ 2), work commitments (n ¼ 2), personal reasons (n ¼ 2), noncompliance (n ¼ 2) and loss to follow-up (n ¼ 2). A total of 50 subjects completed the study.
Study design
Subjects were matched for BMI, gender, age and menopausal status, and then randomly allocated to a high dairy protein/ high-calcium (DP) or high mixed protein/moderate calcium (MP) diet. The study consisted of a 12 wk energy restriction (ER) phase, followed by a 4 wk energy balance (EB) phase. Measurements made at wk 0 represent baseline data, and wk 16 represents the end of the EB phase. Subjects attended the CSIRO Clinical Research Unit (Adelaide, Australia) once every 2 wk for clinical measurements and/or consultation with a qualified dietitian. Body weights were measured and overnight fasting (12 h) venous blood samples were collected in wk 0, 4, 8, 12 and 16. In wk 0 and 16, body composition was assessed and subjects attended the Clinical Research Unit on consecutive days to test insulin and glucose responses following a test meal (meal tolerance test; MTT, day 1) and glucose load (oral glucose tolerance test; OGTT, day 2). The MTT meals (1330 kJ, 32% total energy from protein, 27% fat, 41% carbohydrate, energy density 6.8 kJ/g) comprised foods consistent with subjects' allocated diet (DP low-fat cheese, wholemeal bread, margarine and low-fat yoghurt; MP lean ham, egg, wholemeal bread and fruit biscuit). The glucose load (75 g) was provided in a 200 ml solution. Subjects consumed the meal/beverage in 10 min. Venous blood samples were collected at baseline then 30, 60, 120 and 180 min after commencing the meal/ beverage. During these tests, subjects remained at rest and were permitted to sip water. In wk 0, 12 and 16, urine samples (24 h) were collected for assessment of urea/ creatinine ratio.
Dietary intervention
Both diets were isoenergetic, (5.5 MJ/d), HP (34% energy), moderate carbohydrate (41% energy) and low fat (24% energy). The diets differed in calcium intake (DP 2400 mg/d; MP 500 mg/d) and source of protein foods (listed in descending order of protein content; DP milk, meat, skim milk powder, reduced fat cheese, low-fat yoghurt, egg and MP meat, ham, milk, egg, almonds, legumes). Adjustments to energy intake were made without changing macronutrient profile for active individuals (7 MJ/d). Two standard servings of alcohol (10 g alcohol/serving) were permitted per wk. EB was achieved by increasing energy intake by 2 MJ/d for each 0.5 kg weight loss per wk (averaged over wk [8] [9] [10] [11] [12] . 17 Subjects were provided with a prescriptive meal plan. A weighed food checklist was completed daily to record all food and beverages consumed. Subjects were issued with digital kitchen scales to assist in accurate measurement of portions. Subjects attended consultations with the same dietitian every 2 wk throughout the study for instruction on the dietary requirements, recording food intake and assessment of compliance. In wk 0, 4, 8 and 12, subjects were supplied with foods (B40% of total weekly energy intake) consistent with their allocated diet to encourage compliance. Nutrient analysis was performed on reported intake for 3 d/mo (two weekdays and one weekend), using Food Works Analysis Package 3.0 (Xyris Software, Highgate Hill, Australia), which is based on data from Australian Food Composition Tables.  18 A weighed food record of baseline dietary intake was kept for 3 d prior to commencing the study. Two qualified dietitians conducted all dietary counselling and were trained to provide consistent information to subjects. Biochemistry. Blood for serum was collected in tubes with no additives and allowed to clot at room temperature for 30 min. Blood for plasma was collected in sodium fluoride/ EDTA (1 g/l) tubes and stored on ice until processed. The serum/plasma was isolated by centrifugation for 10 min at 2000 g (51C) (Beckman GS-6R Centrifuge, CA, USA) and stored at À801C. Biochemical analyses were performed after study completion. Serum insulin was measured in duplicate using a commercial radioimmunoassay kit (Pharma AB, Uppsala, Sweden). 19 Serum cholesterol, triacylglycerol and high-density lipoprotein cholesterol (HDL-C) [20] [21] [22] and plasma glucose 23 were determined using enzymatic kits (Hoffman-LaRoche Diagnostics, Basel, Switzerland) and control sera on a Cobas-Bio centrifugal analyser (Roche Diagnostics, Basel, Switzerland). Serum HDL-C was measured after polyethyleneglycol precipitation of low-density lipoprotein cholesterol (LDL-C) and very-low-density lipoprotein cholesterol. LDL-C concentration was determined by a calculation based on the Friedewald equation. 24 LDL À C ¼ðtotal cholesterolÞ À ðtriacylglycerol=2:18Þ À ðHLD À CÞ Total area under the glucose and insulin curves (positive incursions only) during MTT and OGTT was calculated using the trapezoidal equation. 25 C-reactive protein (CRP) was measured using an enzymatic kit (1972855, Roche, Indianapolis, IN, USA) on a Hitachi autoanalyser (Roche, Indianapolis, USA). ELISA was used to analyse soluble intracellular adhesion molecule (s-ICAM) and vascular cell adhesion molecule (VCAM) (immunoKontact, Switzerland), Von Willebrand factor (VWF) (Chromogenix, Italy) and plasminogen activator inhibitor (PAI) (Chromogenix, Italy). Tissue plasminogen activator (tPA) was measured by enzymatic colorimetric assay (Chromogenix, Italy).
Clinical measurements
Total protein (TP), gamma-glutamyltransferase (GGT), bilirubin (BIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were measured on a Hitachi autoanalyser (Roche, Indianapolis, USA) using enzymatic kits (Roche, Indianapolis, USA).
Blood pressure. Systolic and diastolic blood pressure was measured at wk 0, 4, 8, 12 and 16 by automated oscillometry (Dinamapt, 845XT/TX-IEC, FL, USA). This was performed in fasted state while subjects were seated and at rest. The measurement was repeated three times over a 10-min period and results were averaged.
Statistics
All subjects who completed the study were included in data analysis; exclusion of two subjects who did not appear to comply with the dietary protocol (no change in body weight and urinary urea:creatinine) did not affect outcomes or significance. Results are presented for 50 subjects, except DEXA (n ¼ 49 subjects) and urinary analysis (n ¼ 47 subjects) due to incomplete data collection. Statistical analysis was performed using SPSS11.0 for WINDOWS (SPSS Inc., Chicago, USA). Data were normally distributed. An independent t-test was used to assess differences between treatment groups at baseline. Diet data were analysed using an unpaired t-test. The effect of dietary intervention was analysed using repeated measures ANOVA for an effect of time, diet and gender. Data were reanalysed with baseline BMI as a covariate. Differences were considered significant if Po0.05. Data are presented as mean7s.e.m.
Results

Baseline values
There were no significant differences in the physical characteristics, dietary intake or metabolic variables between groups at baseline, except that females in the DP group had significantly higher BMI compared to females in the MP group due to withdrawals that occurred during the intervention (Table 1) .
Dietary compliance and composition
Urinary urea:creatinine excretion (a marker of dietary protein intake) increased 18% above baseline level Table 1 Physical characteristics and usual dietary intake a,b of subjects at baseline (Table 2) . Protein intake during ER and EB was 10673 and 11674 g/d, respectively, and did not differ between groups. Males and females consumed approximately 1.1 and 1.3 g protein/kg total bodyweight, respectively. Dairy sources provided most dietary protein (62%) in the DP diet compared to the MP diet (5%). Calcium intake was also greater in the DP group compared to the MP group (Table 2) . Dietary cholesterol was 28% lower in the DP group compared to the MP group during ER and 36% lower during EB. The two diets differed in the percentage of fat from monounsaturated, polyunsaturated and saturated fatty acids ( Table 2) .
Weight loss and body composition
Females in the DP treatment group had greater total and abdominal fat at baseline compared to females in the MP treatment group (Po0.05) ( Table 3) . Mean weight loss during ER was 10% (À9.773.8 kg) and this was independent of diet and gender. There was no change in weight during EB (wk 12-16). Total fat decreased by 21.871.3% and abdominal fat decreased by 26.372.2% (Po0.0001) ( Table 3 ) with no effect of dietary group. There was a time Â diet Â gender interaction for total body fat and abdominal fat; females in the DP group lost more fat compared to females in the MP group; however, this difference was not significant after controlling for baseline BMI. There was no significant change in lean mass in females after weight loss, and a small reduction in men (P ¼ 0.004), which was independent of total weight loss and diet (Table 3) .
Glycemic control
Fasting insulin reduced by À1.470.3 mU/l at wk 16 compared to baseline (9.170.7mU/l) independent of diet and gender (Po0.05). Fasting glucose did not change throughout the study (wk 0 6.470.1 mmol/l).
Meal tolerance test. The response to the MTT is shown in Figure 1 (panel a, insulin; panel b, glucose) . In wk 0, the insulin concentration at 120 min was 36% higher in the MP group compared to the DP group (Po0.05), although insulin AUC was similar for both groups (DP 7579 mU/l/min; MP 7777 mU/l/min respectively). By wk 16, there was a reduction in insulin AUC independently of diet group (AUC DP À26.078.8 mU/l/min; MP À28.574.1 mU/l/min; Po0.01) (Figure 1, panel a, inset ) and baseline temporal differences were no longer observed.
In wk 0, the postprandial glucose response at 30 and 60 min was significantly higher in the MP group compared to the DP group (Figure 1, panel b) reflected by a difference in glucose AUC at wk 0 (MP 3.870.4 mU/l/min; DP 1.770.4 mU/l/min; Po0.05). By wk 16, the glucose response Oral glucose tolerance test. The response to the OGTT is shown in Figure 2 (panel a, insulin; B glucose). In wk 0, there was no difference in the insulin response to the OGTT between treatments at any time point or for AUC. By wk 16, the insulin AUC was significantly reduced independently of dietary group (DP À41.579.4; MPÀ42.478.4 mU/l/min; Po0.01) (Figure 2, panel a, inset) . The glucose response was not different between dietary groups in wk 0 (Figure 2, panel b) . There was a significant reduction in glucose AUC in wk 16, which was similar for both dietary groups (DP À1.670.6; MPÀ2.770.5 mU/l/min; Po0.01) (Figure 2, panel b, inset) .
Plasma lipid profile
Fasting plasma levels of lipids changed throughout the study, with no differences between dietary groups or gender (Table 4) in response to mixed meals at baseline (wk 0) and after weight loss (wk 16; 12 wk of ER followed by 4 wk of EB) in obese subjects randomized to HP diets: high dairy protein/high calcium (DP; wk 0 K, wk 16 J) and high mixed protein/moderate calcium (MP; wk 0 m, wk 16 n). Change in AUC from wk 0 to 16 inset to the right (DP, black bar; MP, white bar). Subjects consumed a standardized meal consistent with dietary treatment. Differences in response between wk 0 and 16 were analyzed using repeated measures ANOVA (factors, wk and min; between-subject factors, diet and gender). All data are7s.e.m. Insulin and glucose responses were significantly lower at wk 16 compared to wk 0, independent of diet. *Significantly greater than DP at wk 0, Po0.05. in response to OGTT (75 g glucose) at baseline (wk 0) and after weight loss (wk 16; 12 wk of ER followed by 4 wk of EB) in obese subjects randomized to HP diets: high dairy protein /high calcium (DP; wk 0 K, wk 16 J) and high mixed protein/moderate calcium (MP; wk 0 m, wk 16 n). Change in AUC from wk 0 to 16 inset to the right (DP, black bar; MP, white bar). Differences in response between wk 0 and 16 were analyzed using repeated measures ANOVA (factors, wk and min; between-subject factors, diet and gender). All data are mean7s.e.m. *Significantly reduced from wk 0 to 16, Po0.01.
Dietary calcium, dairy foods and weight loss J Bowen et al concentration (Po0.001). Fasting plasma triglycerides decreased by 0.3570.06 mmol/l during ER. By wk 16, there was a 0.2470.06 mmol/l decrease in triglyceride concentration compared to baseline (Po0.001). Fasting plasma HDL-C remained unchanged during the ER and EB phases.
Markers of fibrinolysis, endothelial function and liver function
The fibrinolysis marker PAI-1 was lower at wk 16 compared to baseline (À4.571.4 AU/ml; Po0.001). Endothelial and liver function markers were also reduced at wk 16 compared to baseline (s-ICAM À19.279.8 mg/l; Po0.05, CRP À1.770.4 mg/l; Po0.001, GGT À9.272.0 U/l; Po0.001, AST À5.471.7 U/l; Po0.001 , TPÀ2.270.6 g/l; Po0.001). These changes were independent of dietary treatment (Table 4 ).
Blood pressure
Systolic and diastolic blood pressure were significantly lower at wk 16 compared to baseline independent of dietary group and gender (Table 4) . Overall, systolic blood pressure decreased by 9.471.4 mmHg from baseline to wk 16 (Po0.001). The largest decrease occurred between wk 0 and 4 (À7.671.3 mmHg; Po0.001) and remained relatively stable between wk 4 and 16. Similarly, diastolic blood pressure decreased by 2.570.9 mmHg from baseline to week 16 (Po0.001). The largest decrease occurred between baseline and wk 4 (À4.470.9 mmHg; Po0.001) and remained stable from wk 4 to 12. Diastolic blood pressure increased by 2.170.8 mm Hg from wk 12 to 16 (Po0.01). There was no relationship between baseline blood pressure and weight loss or dietary group.
Discussion
These results do not support the hypothesis that weight loss is enhanced by a high intake of calcium from an energyrestricted diet. We have shown that the efficacy of HP diets in weight loss, body composition and metabolic outcomes is not influenced by protein source. The similarity in weight loss between dietary groups is not likely to be explained by poor dietary compliance. Macronutrient intake was similar to the target dietary composition and reported energy intake reflected changes in body weight. Urea:creatinine excretion (a marker of protein intake) increased equally in both groups, which indicates a similar level of protein intake. There was a difference in fibre content between the DP and MP diets; however, this is unlikely to have affected satiety or energy intake, especially during the ER phase where the difference was B5 g. Fiber supplementation of up to 20-40 g is associated with inconsistent effects on acute energy intake and satiety ratings 26 and long-term weight regulation. 27, 28 Further, all subjects were provided with key foods to consume and prescriptive meal plans. This approach was employed to reduce the likelihood that the foods per se of either group affected compliance. 29 Earlier studies of energy-restricted diets that also differed in calcium intake have not reported any effect of calcium on weight loss. Weight loss in subjects consuming an energyrestricted diet that had a moderate level of protein and lowcalcium content (16% energy from protein, 600 mg Ca/d) was equal to subjects consuming an equicaloric diet that was higher in both protein and calcium (27% energy from protein, 1600 mg Ca/d). 11 Weight reduction in obese women was the same in calcium-supplemented (1800 mg Ca/d) and placebo groups (800 mg Ca/d).
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Our findings contrast a weight loss study (energy deficit of À2 MJ/d for 24 wk) in obese adults where weight loss of subjects allocated to a high dairy diet (1200-1300 mg Ca/d, n ¼ 11) was À10.9% compared to À8.6% in a supplemental calcium group (1200-1300 mg Ca/d, n ¼ 11) and À6.5% in a low-calcium group (500 mg Ca/d, n ¼ 10). 12 Subjects in the present study had a similar baseline BMI and energy intake to the participants in the study by Zemel et al 12 during the intervention. Additionally, the calcium intake of subjects in the DP group was approximately double that of their two higher calcium diets 12 and the calcium intake of the MP diet was similar to their low-calcium group. 12 Despite these parallels in study design, we did not observe a difference in weight loss. It is interesting to note that dairy foods are supplemented with vitamin D in the United States of America (the population tested by Zemel and co-workers). This is not required in the food system of the present study; the 25-hydroxyvitaminD 3 (25-(OH)D) status of the Australia population is determined by exposure to sunlight, which converts 7-dehydrocholesterol to 25-(OH)D. 30 Given that intestinal calcium absorption correlates with circulating concentration of 25-(OH)D, 31 it is possible that a difference in dietary intake of vitamin D between the present study and Zemel et al 12 could have produced differences in calcium absorption. However, it is presumed that in this study the increase in calcium intake resulted in increased calcium absorption, independent of the vitamin D intake and was therefore unlikely to compromise any effect of calcium on weight loss.
Loss of lean mass was low, particularly in females and may reflect a higher protein intake per kg of body weight in females compared to males. This has been previously observed in female participants in high dietary protein, weight loss studies. 14, 32 The OGTT showed that insulin sensitivity improved after weight loss, independent of diet and even though subjects were normoglyemic at baseline. This is consistent with similar studies in hyperinsulinemic and diabetic subjects. 14, 33 The glucose AUC was low for both MTT meals, indicative of the moderate carbohydrate content. The difference between treatments at baseline is probably due to a difference in the glycemic index (GI) of the meals; the predominant carbohydrate in DP meal was lactose, which has a lower GI compared to sucrose from the MP meal. In the absence of weight loss, this indicates a potentially adverse outcome of the MP dietary pattern for overweight subjects who are at increased risk of impaired glycemic control. It also highlights the need to consider aspects other than macronutrient composition when assessing the appropriateness of a dietary strategy.
The improvement in plasma lipid profile was independent of the dietary group. The magnitude of these changes per kilogram of weight loss is similar to earlier findings; 34 however, the largest change occurred within 4 wk of commencing the diet, suggesting that dietary lipid profile and/or ER have a greater impact than total weight loss. Indeed, previous studies have shown that HP diets improve plasma lipid profile in the absence of weight loss. 35, 36 Data on the safety of HP diets are scarce. 37 This study demonstrated that weight loss achieved by HP diets has beneficial effects on markers of cardiovascular function, endothelial function, fibrinolytic markers and liver function. CRP (a strong predictor of cardiovascular disease) is lowered following improvements in insulin sensitivity. 38 Indeed, CRP was reduced by wk 16 in this study and the relatively low glycemic load of both diets may have augmented this reduction. 39 The modest improvements in liver function markers occurred despite subjects being within normal range at baseline. 40 Impressive reductions in blood pressure in hypertensive subjects have been attributed to high dietary calcium intake. 41 A difference between dietary groups due to calcium intake was not anticipated in the present study as subjects were normotensive at baseline. Further, any nutrient-specific effects were likely to be confounded by ER and weight loss. The effect of the DP and MP diets on calcium metabolism is published elsewhere. 42 In summary, we report that weight loss following energyrestricted, HP diets is not affected by dietary calcium or protein source. Glycemic control, lipid profile, markers of liver and vascular function and blood pressure improved with weight loss independent of dietary protein source or calcium intake.
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